Merck Receives FDA Approval For Supplemental Biologics License Application For ENFLONSIA To Expand Indication To Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Children Under Two Years Of Age At Increased Risk For Severe RSV Disease; PDUFA Date Set For March 22, 2027
Merck Receives FDA Approval For Supplemental Biologics License Application For ENFLONSIA To Expand Indication To Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Children Under Two Years Of Age At Increased Risk For Severe RSV Disease; PDUFA Date Set For March 22, 2027
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day